Skip to main content
Explore URMC
menu

Daniel L. Mulkerin, M.D.

Contact Information

Phone Numbers

Appointment: (585) 276-3000

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

Professional Background

Dr. Mulkerin's clinical practice is focused on gastrointestinal malignancies. He is actively involved in clinical research. He is a highly respected mentor and has extensive teaching experience. Dr. Mulkerin holds an important role in enhancing and advancing the Department of Medicine's footprint in our region.

Credentials

Education

1992
MD | Thomas Jefferson University Hospital (USA)

Post-doctoral Training & Residency

07/01/1996 - 06/30/1999
Fellowship in Medical Oncology at University of Wisconsin Hospital and Clinics

06/25/1993 - 06/30/1996
Residency in Internal Medicine at University of Wisconsin Hospital and Clinics

06/24/1992 - 06/24/1993
Internship in Internal Medicine at University of Wisconsin Hospital and Clinics

VIEW ALL expand_more

Awards

2017 - 2018
Award for Service/Leadership Excellence

2016
UW Health Patient Experience Physician Champion Award

2015
UW Health Physician Excellence Regional Services Award

2014
UW Health Patient Experience Physician Champion Award

2013 - 2021
Top Doctor's in America

2006
Top Doctors: Madison Magazine

1992
Hobart Armory Hare Honor Society
Location: Jefferson Medical College


UW Hematology/Oncology Division/Department of Medicine

VIEW ALL expand_more

Clinical Trials

An Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Lead Researcher: Daniel L Mulkerin

The main purpose of this research study is to determine the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic ductal adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression.

View Study Details

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Lead Researcher: Daniel L Mulkerin

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).

View Study Details

Publications

Journal Articles

7/2022
Krause D, Sharrah K, Gross A, Bowers D, Mulkerin D, Brandt N, Kennedy K, Austin A, Begue A, Bell R, Raczyk C, Pickard T, Kubal T, Johnson D, Jeffries K, Dest V, Randall R, Sugalski J, Zecha G. "Measuring Advanced Practice Provider Productivity at the National Comprehensive Cancer Network's Member Institutions." Journal of the advanced practitioner in oncology.. 2022 Jul; 13(5):507-513. Epub 2022 Jul 27.

6/2022
Emamekhoo H, Carroll CB, Stietz C, Pier JB, Lavitschke MD, Mulkerin D, Sesto ME, Tevaarwerk AJ. "Supporting Structured Data Capture for Patients With Cancer: An Initiative of the University of Wisconsin Carbone Cancer Center Survivorship Program to Improve Capture of Malignant Diagnosis and Cancer Staging Data." JCO clinical cancer informatics.. 2022 Jun; 6:e2200020.

9/2021
Austin A, Jeffries K, Krause D, Sugalski J, Sharrah K, Gross A, Bowers D, Mulkerin D, Brandt N, Begue A, Bell R, Raczyk C, Pickard T, Johnson D, Dest V, Randall R, Zecha G, Kennedy K. "A Study of Advanced Practice Provider Staffing Models and Professional Development Opportunities at National Comprehensive Cancer Network Member Institutions." Journal of the advanced practitioner in oncology.. 2021 Sep; 12(7):717-724. Epub 2021 Sep 01.

VIEW ALL PUBLICATIONS